Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients
NCT ID: NCT00560157
Last Updated: 2013-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
22 participants
INTERVENTIONAL
2002-12-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
Sondalis HP
Crucial (enteral tube feeding)
Evaluation of new enteral product, Crucial, in ICU patients
II
Crucial
Crucial (enteral tube feeding)
Evaluation of new enteral product, Crucial, in ICU patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Crucial (enteral tube feeding)
Evaluation of new enteral product, Crucial, in ICU patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* requiring the administration of an exclusive tube feeding nutrition during 7 days and beginning at the latest in the three days following the aggression
* ICU patients hospitalized for:
* neurologic affections
* pneumopathy
* major abdominal surgery or serious acute pancreatitis
* written informed consent
Exclusion Criteria
* immunosuppressive therapy
* radiotherapy or chemotherapy in the last six month
* uncontrolled septic choc
* auto-immune disease
* hepatic,renal or digestive insufficiency
* hyperlipidemia
* diabetes mellitus type 1
* digestive malabsorption
* life threatening situation
* treatments with growing hormone, glutamine or its metabolites or precursors such as ornithine alpha keto glutarate
18 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société des Produits Nestlé (SPN)
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luc CYNOBER, PhD
Role: STUDY_CHAIR
University PARIS V
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital A. BECLERE
Clamart, , France
Hopital Saint Antoine
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCNF 0401
Identifier Type: -
Identifier Source: org_study_id